C4B and myeloproliferative neoplasm: In contrast with the approach of Weeks et al., Gu et al. modeled each MN subtype separately; made no distinction among CH, CHIP, or CCUS; and generated quantitative, time-dependent predictions of MN-free survival for each MN subtype (AML, MDS, MPN).